SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (520)4/30/2001 6:32:22 PM
From: scaram(o)uche  Respond to of 1833
 
BM:

I'll leave it to you to determine the equivalence of all shares, I'm not going to duplicate the research.

You've solicited comments......

1. You've first-blush hit the valuation square on the head.

2. You've brought an unexpected gift! Not too many investors would have thought to pursue the info there.

Thank you, thank you, thank you, thank you!!!!

Rick



To: BulbaMan who wrote (520)4/30/2001 7:05:45 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1833
 
So, $2.40/share, cash plus Axiom, plus all that nice potential royalty flow.

Again, I consider it very likely that at least a portion of the milestones will be achieved. I therefore feel that interest, license renewals for EXISTING contracts, and milestone revenues will more than cover "attorney burn".

Reasonable conclusion....... no burn for the foreseeable future, maybe even a tad of profit.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News